COBRE Center for Antimicrobial Resistance and Therapeutic Discovery - Administrative Core

Miriam医院热情推荐Erika D‘Agata，医学博士，公共卫生硕士，被任命为抗菌素耐药性和治疗发现中心(CARTD)项目主任/首席研究员(PD/PI)，自2023年3月1日起生效。 管理核心 摘要/摘要 行政核心将提供财政、科学和技术管理 位于米里亚姆的科布雷抗菌素耐药性和治疗发现中心 医院。核心主任Mylonakis在NAU副主任的协助下，将建立 总体规划目标。这些目标和实现这些目标的进展将是 由指导委员会、外部咨询委员会、高级学院指导委员会监督 和咨询委员会(SFMAC)以及NIGMS的项目工作人员。我们中心的总体使命是 营造一种激励个人追求严谨实验室科学的环境 通过我们的核心设施提供技术和指导支持。我们会继续推行 以下具体目标：(1)核心将维持一个组织结构，以确保 监督、科学、行政和服务导向之间的有效沟通 科布雷的组件。(2)：核心将制定战略，以增加CARDT的使用 到第三阶段结束时允许自我维持的核心。(3)：核心将提供严格的 指导所有CARDT主要/试点调查人员的基础设施。(4)：核心将管理 旨在支持最有价值的抗菌剂研究的试点赠款计划 耐药性和药物开发。

The Miriam Hospital enthusiastically recommends Erika D’Agata, MD, MPH of to be appointed as The Center for Antimicrobial Resistance and Therapeutic Discover (CARTD) Program Director/Principal Investigator (PD/PI) effective March 1, 2023. Administrative Core Summary/Abstract The Administrative Core will provide financial, scientific and technologic stewardship of the COBRE Center for Antimicrobial Resistance and Therapeutic Discovery (CARTD) at The Miriam Hospital. Core Director Mylonakis, with the assistance of Deputy Director Nau, will establish overall programmatic goals. These goals and progress toward accomplishing them will be monitored by the Steering Committee, External Advisory Committee, Senior Faculty Mentoring and Advisory Committee (SFMAC) and Program Staff at NIGMS. Our Center’s overall mission is to foster an environment that inspires individuals to pursue rigorous laboratory science by providing technical and mentoring support through our core facilities. We will pursue the following specific aims: (1): The Core will maintain an organizational structure that ensures effective communication between the supervisory, scientific, administrative and service oriented components of the COBRE. (2): The Core will devise strategies to increase the use of CARDT Cores to allow self-sustainability by the end of Phase III. (3): The Core will provide a rigorous mentoring infrastructure to all CARDT principal/pilot investigators. (4): The Core will manage a Pilot Grants Program designed to support the most meritorious research on antimicrobial resistance and drug development.